My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Kamron Laboratories announces resignation of company secretary & compliance officer
Dec 13,2016

Kamron Laboratories announced that the Board of Directors, in their meeting held on 12 December 2016, have taken note of resignation of Dhaval Patel, as a Company Secretary and Compliance Officer of the Company.

Powered by Capital Market - Live News

Swan Energy commences construction of LNG terminal at Jafrabad Gujarat
Dec 13,2016

Swan Energy announced that:

1. Swan Energy, through its 100% subsidiary company Swan LNG Private (SLPL), has received approval from Gujarat Maritime Board (GMB) for commencement of construction of LNG terminal with ancillary structures for its Floating Storage and Re-gasification Unit (FSRU) Project at Jafrabad, Gujarat.

2. SLPL has executed an EPC contract for Marine and Dredging works worth Rs. 2115 crore with National Marine & Infrastructure India (NMIIPL) for carrying out the construction of LNG terminal at Jafrabad, Gujarat, to be completed within 3 years. NMIIPL has already started the construction works.

Powered by Capital Market - Live News

Board of Vascon Engineers approves sale of stake in Viorica Hotels
Dec 13,2016

Vascon Engineers announced that the Board of Directors of the Company at its meeting held on 13 December 2016 approved the sale of its holding in Viorica Hotels for a consideration of Rs. 15.60 crore.

Powered by Capital Market - Live News

Swan Energy spurts after subsidiary receives maritime boards approval for LNG terminal
Dec 13,2016

The announcement was made during market hours today, 13 December 2016.

Huge volumes were witnessed on the counter. On the BSE, 17.33 lakh shares were traded in the counter so far as against average daily volume of 3.35 lakh shares in the past one quarter. The stock was locked at a high of Rs 201.35 in intraday trade. The stock hit a low of Rs 169.85 so far during the day.

The stock had outperformed the market over the past one month till 12 December 2016, jumping 25.13% compared with the 1.13% decline in the Sensex. The scrip had also outperformed the market in past one quarter, jumping 167.2% as against Sensexs 6.48% decline.

The small-cap company has an equity capital of Rs 22.12 crore. Face value per share is Re 1.

Swan Energy announced that through its 100% subsidiary company, Swan LNG (SLPL), has received approval from Gujarat Maritime Board (GMB) for commencement of construction of liquified natural gas (LNG) terminal with ancillary structures for its floating storage and re-gasification unit (FSRU) project at Jafrabad, Gujarat.

SLPL has executed an engineering, procurement and construction (EPC) contract for marine and dredging works worth Rs 2115 crore with National Marine & Infrastructure India (NMIIPL) for carrying out the construction of LNG terminal at Jafrabad, Gujarat, to be completed within 3 years. NMIIPL has already started the construction works.

Swan Energys net profit jumped 1170.6% to Rs 2.16 crore on 1.6% growth in net sales to Rs 96.09 crore in Q2 September 2016 over Q2 September 2015.

Swan Energy is an emerging green energy company with a pipeline of innovatively structured power projects.

Powered by Capital Market - Live News

Dominos Pizza offers cashless payment option
Dec 13,2016

Dominos Pizza announced a cashless payment option for home delivery orders. With this service, customers call to order and chose to pay with a cashless option, they would be immediately sent a link through SMS on their mobile phone. This link would take the customers to the payment gateway where they choose to pay with a debit card, credit card, net banking or wallet.

Powered by Capital Market - Live News

Intellect Design Arena leads gainers in A group
Dec 13,2016

Intellect Design Arena surged 4.58% to Rs 172.45 at 13:45 IST. The stock topped the gainers in the BSEs A group. On the BSE, 5.28 lakh shares were traded on the counter so far as against the average daily volumes of 2.61 lakh shares in the past two weeks.

South Indian Bank jumped 3.71% at Rs 22.35. The stock was second biggest gainer in A group. On the BSE, 5.62 lakh shares were traded on the counter so far as against the average daily volumes of 4.81 lakh shares in the past two weeks.

Kotak Mahindra Bank gained 3.4% to Rs 110.90. The stock was the third biggest gainer in A group. On the BSE, 2.09 lakh shares were traded on the counter so far as against the average daily volumes of 3.89 lakh shares in the past two weeks.

Fortis Healthcare gained 3.11% at Rs 175.50. The stock was the fourth biggest gainer in A group. On the BSE, 75,000 shares were traded on the counter so far as against the average daily volumes of 78,000 shares in the past two weeks.

NCC rose 2.87% to Rs 84.10. The stock was the fifth biggest gainer in A group. On the BSE, 10.37 lakh shares were traded on the counter so far as against the average daily volumes of 4.63 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Hinduja Global Solutions to hire 1225 position in Canada
Dec 13,2016

Hinduja Global Solutions announced the availability of 1,225 career opportunities at its customer experience centers throughout Canada. Thepositions, are expected to meet increasing client needs as well as fuel the companys expansion in the country. HGS will hold three open houses to recruit permanent, full-time inbound customer service representatives.

Powered by Capital Market - Live News

ADB scales down Indias growth forecast to 7% for 2016
Dec 13,2016

Economic growth in developing Asia remains broadly stable, but a slight slowdown in India has trimmed the regions growth outlook for 2016, says a new Asian Development Bank (ADB) report. In a supplement to its Asian Development Outlook 2016 Update report, ADB has downgraded 2016 growth to 5.6%, below its previous projection of 5.7%. For 2017, growth remains unchanged at 5.7%.

Asian economies continue their robust expansion in the face of global economic uncertainties, said ADB Deputy Chief Economist Juzhong Zhuang. Structural reforms to boost productivity, improve investment climate, and support domestic demand can help maintain growth momentum into the future.

Combined growth for the major industrial economies exceeded expectations in the Update, ticking up 0.1 percentage point to 1.5% in 2016. Growth in 2017 is maintained at 1.8%. Robust consumer spending supported the US economy, with supportive monetary policy and improved labor markets fueling growth in the euro area. Japans expansion, meanwhile, will be buoyed by strong exports, despite the stronger local currency.

ADB has downgraded the forecast in South Asia from 6.9% to 6.6% in 2016. Growth will bounce back in 2017, reaching 7.3%. Indias tempered growth projection to 7.0% from the previously forecasted 7.4% in 2016 is due to weak investments, a slowdown in the countrys agriculture sector, and the lack of available cash due to the governments decision to ban high-denomination banknotes. This will likely affect largely cash-based sectors in the country including small- and medium-scale businesses. The effects of the transition are expected to be short-lived and the Indian economy is expected to grow at 7.8% in 2017.

The forecast in East Asia is maintained for 2016 and 2017. Growth this year will reach 5.8%, with a slight moderation to 5.6% in 2017. Growth in the Peoples Republic of China (PRC) - the worlds second largest economy - is expected to hit 6.6% this year, driven by strong domestic consumption, solid wage growth, urban job creation, and public infrastructure investment. The forecast for the PRC in 2017 is maintained at 6.4%.

In Southeast Asia, growth forecasts remain unchanged at 4.5% in 2016 and 4.6% in 2017, with Malaysia and the Philippines expecting stronger growth due to a surge in domestic consumption and public and private investment, compared to lower growth forecasts in Brunei Darussalam, Myanmar, and Singapore.

The outlook in Central Asia is maintained at 1.5% in 2016 and 2.6% in 2017, as the ongoing recession in the Russian Federation and low global commodity prices for oil and natural gas continue to dampen growth in the subregion.

The Pacific will see growth of 2.7% in 2016, picking up to 3.3% in 2017. The fiscal contraction in Papua New Guinea - the Pacifics largest economy - and recovery from recent cyclones have weighed on growth in the subregion. While cyclone damage in Fiji has had a bigger impact on its growth outlook than previously envisaged, prospects for Samoa, Kiribati, and Tuvalu are improving through improvements in fisheries, infrastructure, and tourism.

Powered by Capital Market - Live News

Prime Securities to announce December quarter results
Dec 13,2016

Prime Securities announced that a Meeting of the Board of Directors of the Company is scheduled to be held on 03 January 2017, inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended 31 December 2016.

Powered by Capital Market - Live News

Menon Bearings announces resignation of Chairman
Dec 13,2016

Menon Bearings announced that due to age, Ram Menon has not been able to attend Board meetings and has stepped down as Chairman and resigned as Director of the Company.

Powered by Capital Market - Live News

Biocon provides update on subsidiary - Syngene International
Dec 13,2016

Biocon announced that there was a fire on the night of 12 December 2016 within one of the laboratory buildings at Syngene International, a subsidiary of the Company. The fire has since been brought under control and there has been no loss of life or any injury reported. Syngene is in the process of assessing the extent of damage to the building and equipment and also implementing a business continuity plan to minimize impact on operations.

Other facilities at Syngene are not impacted and continue to operate as normal.

Powered by Capital Market - Live News

Shilpa Medicare gets approval for Capecitabine Tablets
Dec 13,2016

Shilpa Medicare has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.

Powered by Capital Market - Live News

Artson Engineering jumps after receiving contract
Dec 13,2016

The announcement was made during market hours today, 13 December 2016.

Meanwhile, the BSE Sensex was up 86.19 points, or 0.33%, to 26,601.43.

More than usual volumes were witnessed on the counter. On the BSE, 55,599 shares were traded in the counter so far as against an average daily volume of 13,661 shares in the past one quarter. The stock hit high of Rs 51 and low of Rs 44.75 so far during the day. The stock had hit a 52-week high of Rs 64.90 on 23 December 2015. The stock had hit a 52-week low of Rs 34 on 1 March 2016.

The stock had underperformed the market over the past one month till 12 December 2016, falling 16.09% compared with the 1.13% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 19.87% as against Sensexs 6.48% decline.

The small-cap company has an equity capital of Rs 3.69 crore. Face value per share is Re 1.

Artson Engineering said that the contract is for design, detailed engineering, supply, fabrication, installation, testing, foundation work, fire protection, other civil works for double deck floating roof type crude oil storage tanks in Odisha, India.

Artson Engineering reported net profit of Rs 0.49 crore in Q2 September 2016, as compared with net loss of Rs 0.07 crore in Q2 September 2015. Net sales rose 1.3% to Rs 26.02 crore in Q2 September 2016 over Q2 September 2015.

Artson Engineering is a project engineering company. It offers multi-disciplinary design and construction services in the mechanical, civil, electrical and instrumentation fields. It offers turnkey services in petroleum storage and handling systems, plant utilities, diesel power houses, CPP, energy conservation, waste-heat recovery and noise pollution control systems.

Powered by Capital Market - Live News

Yes Bank gets upgradation in ESG ratings
Dec 13,2016

Yes Bank has been upgraded by MSCI ESG Research to AAA rating from AA rating.

Powered by Capital Market - Live News

Sun Pharma advances after signing exclusive global licensing deal with Moebius Medical
Dec 13,2016

The announcement was made after market hours yesterday, 12 December 2016.

Meanwhile, the BSE Sensex was up 70.19 points, or 0.26%, to 26,585.43.

On the BSE, 1.5 lakh shares were traded in the counter so far as against average daily volume of 4.7 lakh shares in the past one quarter. The stock had hit a high of Rs 682.50 and low of Rs 666.60, so far during the day. The stock had hit a 52-week high of Rs 898 on 23 February 2016. The stock had hit a 52-week low of Rs 572.40 on 9 November 2016.

The stock had underperformed the market over the past one month till 12 December 2016, falling 1.84% compared with the 1.13% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 14.06% as against Sensexs 6.48% decline.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

Sun Pharmaceutical Industries and Israel-based Moebius Medical, a biotechnology company that is developing novel pain relief treatments for osteoarthritis have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis.

MM-II is a novel non-opioid product that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction.

MM-II is an intra-articular biolubricant injection which is being developed to provide symptomatic relief of mild-to-moderate osteoarthritis pain. The product is based on patent-protected technology licensed by Moebius Medical from the Hebrew University of Jerusalem, Technion Israel Institute of Technology and Hadassah Medical Centre.

According to the agreement, Sun Pharma will fund further development of Moebius Medicals lead product, MM-II, and undertake its global commercialization. To date, Moebius Medical has completed a first-in-man clinical study at Hadassah Medical Center, demonstrating the products fast onset of action and its potentially better efficacy and comparable safety for alleviating osteoarthritis pain as compared to Hyaluronic Acid injection.

Moebius Medical will conduct requisite pre-clinical studies and will assume responsibility for product development and manufacturing through the end of phase-II studies. Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialization. Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma.

On a consolidated basis, Sun Pharmaceutical Industries net profit surged 117.3% to Rs 2235.14 crore on 13.2% growth in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.

Sun Pharmaceutical Industries is the worlds fifth largest specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News